Introduction and Objective: Insulin resistance is a major risk factor in the development of type 2 diabetes (T2D) and metabolic syndrome. Although ~25% of people within the general non-diabetic population are insulin resistant, the primary underlying cause of insulin resistance remains elusive.Methods: In this study, we have used induced pluripotent stem cells (iPSC) derived from […]
Read MoreAuthor: sugaradmin
1757-P: Development of an Ultra-Stable Insulin That Can Withstand Heat
Introduction and Objective: We are developing an ultra-stable insulin analog designed to address the intrinsic physical instability of current insulin formulations. Using advanced protein structural insights and protein engineering approaches originating from UT Southwestern, we focused on optimizing insulin analogs to reduce fibrillation and aggregation while improving resistance to thermal and mechanical stress across a […]
Read More2031-P: Correlation of Minoritized Ethnicity Representation between Patients and Staff of Diabetes Centers Involved in the T1D Exchange Quality Improvement Collaborative
Introduction and Objective: T1D Exchange Quality Improvement Collaborative (T1DX-QI) administered a survey to evaluate characteristics of patient and clinic workforce and QI initiatives underway to support people with type 1 and type 2 diabetes (PwT1D and PwT2D).Methods: The T1DX-QI survey was administered August-October 2025 to collect 2024 data. Descriptive analyses summarized racial/ethnic diversity of clinical […]
Read More2592-P: Impact of Once-Weekly Injectable Semaglutide vs. Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP1)
Introduction and Objective: Fatty liver index (FLI) is a diagnostic tool in metabolic dysfunction-associated steatotic liver disease, an end-organ complication in overweight/obesity. This post hoc analysis assessed the impact of injectable semaglutide (sema) 2.4 mg versus placebo on FLI scores in STEP 1.Methods: People with information needed to calculate FLI scores (BMI, waist circumference, triglycerides […]
Read More2715-LB: Short Lipidated Peptide (SLiP) Targeting Nav1.8 for Treating Neuropathic Pain
Introduction and Objective: Diabetic peripheral neuropathy remains a major therapeutic challenge, with over 50% of patients responding inadequately to existing non-opioid therapies (gabapentinoids, SNRIs, TCAs). Dorsal root ganglion (DRG) neurons serve as the primary sites for injury-induced plasticity underlying painful peripheral pathophysiologies. Voltage-gated sodium channels (VGSC), specifically Nav1.8, are highly expressed in DRGs and are […]
Read More1395-P: Effect of the Dual GLP-1/GIP Receptor Agonist Tirzepatide on Circulating Proteins Associated with ESKD Risk in Patients with Type 2 Diabetes
Introduction and Objective: In the SURPASS-4 clinical trial in patients with type 2 diabetes (T2D) at high cardiovascular risk, once-weekly treatment with the dual GLP-1/GIP receptor agonist, tirzepatide (TZP) resulted in substantial weight reduction, slower kidney function decline, and reduced albuminuria compared to insulin glargine. This post-hoc analysis evaluated the effect of TZP on 52-week […]
Read More2482-P: Metabolic Obesity Phenotypes and Advanced Liver Fibrosis: A Cross-Sectional Transient Elastography Study
Introduction and Objective: Body mass index (BMI) alone may miss obesity risk; ICMR-INDIAB study supports metabolic phenotyping into four groups based on their metabolic and BMI status: metabolically healthy non-obese (MHNO), metabolically obese non-obese (MONO), metabolically obese obese (MOO), and metabolically healthy obese (MHO). We assessed phenotype distribution and association with liver fibrosis stage using […]
Read More2929-LB: Implementing a FibroScan Clinic in Primary Care: A Pilot Program
Introduction and Objective: The rates of screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis-4 (FIB-4) index is slowly increasing in the primary care setting. Access to Vibration-Controlled Transient Elastography (FibroScan) remains a barrier in identifying high-risk MASLD and is currently underutilized. We evaluate an approach to implementation of […]
Read More1862-P: Medicaid Beneficiaries with Type 1 and Type 2 Diabetes Achieve ADA-Recommended Glycemic Targets Using the MiniMed 780G System
Introduction and Objective: People with diabetes (PWD) who are beneficiaries of Medicaid have worse glycemic outcomes than those with private insurance and are at increased risk for poor clinical outcomes. Barriers to accessing automated insulin delivery (AID) systems include age, complex/extensive prior authorization policies, unclear documentation requirements, and healthcare provider implicit bias about who is […]
Read More2784-LB: Real-World Weight Loss Outcomes among Adults with Type 2 Diabetes Using an AI-Enabled Weight Management Mobile App
Introduction and Objective: Mobile app-based weight management programmes using artificial intelligence (AI) coaching are increasingly used to support lifestyle change in people with type 2 diabetes (T2D), but real-world outcomes remain limited. The aim of this study was to evaluate weight loss among adults with T2D using an AI-enabled weight management app, and to examine […]
Read More